Alnylam authorizes $1 billion stock buyback, announces commercial chief's departure
Alnylam's board approved a new $1 billion repurchase program as the company's chief commercialization officer plans to leave in December 2026.
SEC filing
5 stories
Alnylam's board approved a new $1 billion repurchase program as the company's chief commercialization officer plans to leave in December 2026.
SEC filing
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
Alnylam reported $1,292 million in quarterly net product revenue, expanded its nucresiran Phase 3 study to 2,250 patients, and reported Phase 1 data for brezosiran in Huntington's disease.
SEC filing (2)